1. Home
  2. ATNM vs BAFN Comparison

ATNM vs BAFN Comparison

Compare ATNM & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.20

Market Cap

36.8M

Sector

Health Care

ML Signal

N/A

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$5.92

Market Cap

30.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ATNM
BAFN
Founded
2000
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
36.8M
30.9M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ATNM
BAFN
Price
$1.20
$5.92
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
115.6K
11.9K
Earning Date
01-01-0001
04-30-2026
Dividend Yield
N/A
1.27%
EPS Growth
30.60
133.93
EPS
N/A
N/A
Revenue
$81,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$5.72
52 Week High
$1.95
$19.00

Technical Indicators

Market Signals
Indicator
ATNM
BAFN
Relative Strength Index (RSI) 53.29 38.60
Support Level $1.02 $5.72
Resistance Level $1.71 $8.57
Average True Range (ATR) 0.07 0.31
MACD 0.02 -0.09
Stochastic Oscillator 81.40 23.75

Price Performance

Historical Comparison
ATNM
BAFN

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: